Literature DB >> 16940127

In vitro activity of daptomycin against methicillin-resistant Staphylococcus aureus, including heterogeneously glycopeptide-resistant strains.

Bram M W Diederen1, Inge van Duijn, Piet Willemse, Jan A J W Kluytmans.   

Abstract

The purpose of the present study was to assess the in vitro activity of daptomycin against a well-defined collection of methicillin-resistant Staphylococcus aureus (MRSA) isolates (n = 98), including heterogeneously glycopeptide-resistant MRSA (hGISA) strains. Susceptibility testing was performed by using the Etest system. Daptomycin was potent against both glycopeptide-susceptible and hGISA strains.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16940127      PMCID： PMC1563506          DOI： 10.1128/AAC.00526-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  In vitro bactericidal activity of daptomycin against staphylococci.

Authors:  Peter C Fuchs; Arthur L Barry; Steven D Brown
Journal:  J Antimicrob Chemother       Date:  2002-03       Impact factor: 5.790

2.  In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers.

Authors:  A L Barry; P C Fuchs; S D Brown
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

3.  Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene.

Authors:  Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

4.  In vitro activity of daptomycin against gram-positive European clinical isolates with defined resistance determinants.

Authors:  Ad C Fluit; Franz-Josef Schmitz; Jan Verhoef; Dana Milatovic
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

5.  An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus.

Authors:  Jean B Patel; Laura A Jevitt; Jeffery Hageman; L Clifford McDonald; Fred C Tenover
Journal:  Clin Infect Dis       Date:  2006-06-01       Impact factor: 9.079

6.  Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides.

Authors:  T R Walsh; A Bolmström; A Qwärnström; P Ho; M Wootton; R A Howe; A P MacGowan; D Diekema
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

7.  In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin- intermediate and -resistant strains.

Authors:  M J Rybak; E Hershberger; T Moldovan; R G Grucz
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Performance of CHROMagar selective medium and oxacillin resistance screening agar base for identifying Staphylococcus aureus and detecting methicillin resistance.

Authors:  Jan Kluytmans; Arjanne Van Griethuysen; Piet Willemse; Peter Van Keulen
Journal:  J Clin Microbiol       Date:  2002-07       Impact factor: 5.948

9.  High percentage of methicillin-resistant Staphylococcus aureus isolates with reduced susceptibility to glycopeptides in The Netherlands.

Authors:  Arjanne Van Griethuysen; Annemarie Van 't Veen; Anton Buiting; Timothy Walsh; Jan Kluytmans
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

Review 10.  Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

Authors:  Christopher F Carpenter; Henry F Chambers
Journal:  Clin Infect Dis       Date:  2004-03-11       Impact factor: 9.079
View more
  8 in total

1.  Hydrophobic interactions modulate antimicrobial peptoid selectivity towards anionic lipid membranes.

Authors:  Konstantin Andreev; Michael W Martynowycz; Mia L Huang; Ivan Kuzmenko; Wei Bu; Kent Kirshenbaum; David Gidalevitz
Journal:  Biochim Biophys Acta Biomembr       Date:  2018-04-03       Impact factor: 3.747

Review 2.  Daptomycin: a review of its use in the management of complicated skin and soft-tissue infections and Staphylococcus aureus bacteraemia.

Authors:  Philip I Hair; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Study of Antibiotic Resistance Pattern in Methicillin Resistant Staphylococcus Aureus with Special Reference to Newer Antibiotic.

Authors:  Dardi Charan Kaur; Sadhana Sanjay Chate
Journal:  J Glob Infect Dis       Date:  2015 Apr-Jun

4.  Activity of antimicrobial peptides and conventional antibiotics against superantigen positive Staphylococcus aureus isolated from patients with atopic dermatitis.

Authors:  Izabela Błażewicz; Maciej Jaśkiewicz; Lidia Piechowicz; Damian Neubauer; Roman J Nowicki; Wojciech Kamysz; Wioletta Barańska-Rybak
Journal:  Postepy Dermatol Alergol       Date:  2018-02-20       Impact factor: 1.837

5.  The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.

Authors:  P E Pertel; B I Eisenstein; A S Link; B Donfrid; E J A Biermann; P Bernardo; W J Martone
Journal:  Int J Clin Pract       Date:  2009-03       Impact factor: 2.503

6.  In vitro activity of daptomycin & linezolid against methicillin resistant Staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in Central India.

Authors:  Sheetal Chitnis; Gunjan Katara; Nanda Hemvani; Siddika Pareek; Dhananjay Sadashiv Chitnis
Journal:  Indian J Med Res       Date:  2013-01       Impact factor: 2.375

Review 7.  Daptomycin: an evidence-based review of its role in the treatment of Gram-positive infections.

Authors:  Armando Gonzalez-Ruiz; R Andrew Seaton; Kamal Hamed
Journal:  Infect Drug Resist       Date:  2016-04-15       Impact factor: 4.003

8.  Vancomycin, linezolid and daptomycin susceptibility pattern among clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) from Sub- Himalyan Center.

Authors:  Afzal Husain; Vinita Rawat; Mukesh Kumar; Pankaj Kumar Verma
Journal:  J Lab Physicians       Date:  2018 Apr-Jun
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.